Data show that three of the fifty-seven Alzheimer’s disease-related clinical trials funded by the National Institute on Aging are related to SV2A, and the study of LEV and AGB101 (levetiracetam antagonist) has entered phase II/III trials, which suggests that SV2A is a potential marker for detecting synaptic density. Here, SV2A is linked to early-onset autosomal dominant Alzheimer disease.